Stephen K.  Brannan net worth and biography

Stephen Brannan Biography and Net Worth

Dr. Brannan is a neuroscience drug development expert who has held senior positions overseeing both clinical development and medical affairs with more than 15 years of industry experience.  Previously, Dr. Brannan was the Therapeutic Head of Neuroscience at Takeda and Vice President for Clinical Research and Medical Affairs at Forum Pharmaceuticals. Dr. Brannan has been active in the development of multiple important central nervous system treatments including Cymbalta®, Exelon Patch®, Trintellix®, and Vagal Nerve Stimulation for Treatment Resistant Depression while holding various senior roles at Forum, Takeda, Novartis, Cyberonics, and Eli Lilly. His experience includes drug development, registration, medical affairs, launch and lifecycle management across psychiatry and neurology programs.  Dr. Brannan is a member of several scientific societies and groups, including ACNP, ISCTM (member of the Executive and Scientific Program Committees), ISCDD, AARR, IOM Neuroforum, and CNS Summit (founding member and member of the Leadership Council).

Prior to joining the pharmaceutical industry, Dr. Brannan worked on the faculty at the University of Texas Health Science Center at San Antonio (UTHSCSA) where he specialized in seeing mood and anxiety disorder patients, ran a clinical research unit, and did neuroimaging research at the Research Imaging Center.

Dr. Brannan trained in psychiatry at UTHSCSA and holds an M.D. from the University of Texas Health Science Center at Dallas (Southwestern Medical School). He has over 40 publications and routinely gives invited talks and presentations at industry conferences.

What is Stephen K. Brannan's net worth?

The estimated net worth of Stephen K. Brannan is at least $14.05 million as of March 8th, 2024. Dr. Brannan owns 42,604 shares of Karuna Therapeutics stock worth more than $14,052,077 as of May 19th. This net worth evaluation does not reflect any other investments that Dr. Brannan may own. Additionally, Dr. Brannan receives an annual salary of $751,750.00 as Insider at Karuna Therapeutics. Learn More about Stephen K. Brannan's net worth.

How old is Stephen K. Brannan?

Dr. Brannan is currently 68 years old. There are 3 older executives and no younger executives at Karuna Therapeutics. Learn More on Stephen K. Brannan's age.

What is Stephen K. Brannan's salary?

As the Insider of Karuna Therapeutics, Inc., Dr. Brannan earns $751,750.00 per year. The highest earning executive at Karuna Therapeutics is Dr. Andrew Craig Miller Ph.D., Founder and President of Research & Development, who commands a salary of $835,400.00 per year. Learn More on Stephen K. Brannan's salary.

How do I contact Stephen K. Brannan?

The corporate mailing address for Dr. Brannan and other Karuna Therapeutics executives is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. Karuna Therapeutics can also be reached via phone at (857) 449-2244 and via email at [email protected]. Learn More on Stephen K. Brannan's contact information.

Has Stephen K. Brannan been buying or selling shares of Karuna Therapeutics?

Stephen K. Brannan has not been actively trading shares of Karuna Therapeutics over the course of the past ninety days. Most recently, Stephen K. Brannan sold 5,000 shares of the business's stock in a transaction on Friday, March 8th. The shares were sold at an average price of $318.34, for a transaction totalling $1,591,700.00. Following the completion of the sale, the insider now directly owns 42,604 shares of the company's stock, valued at $13,562,557.36. Learn More on Stephen K. Brannan's trading history.

Who are Karuna Therapeutics' active insiders?

Karuna Therapeutics' insider roster includes Stephen Brannan (Insider), James Healy (Director), Troy Ignelzi (CFO), Jeffrey Jonas (Director), Andrew Miller (COO), Laurie Olson (Director), Atul Pande (Director), Steven Paul (CEO), and Heather Preston (Director). Learn More on Karuna Therapeutics' active insiders.

Are insiders buying or selling shares of Karuna Therapeutics?

In the last twelve months, insiders at the sold shares 12 times. They sold a total of 89,119 shares worth more than $20,412,131.47. The most recent insider tranaction occured on March, 8th when insider Stephen K Brannan sold 5,000 shares worth more than $1,591,700.00. Insiders at Karuna Therapeutics own 13.2% of the company. Learn More about insider trades at Karuna Therapeutics.

Information on this page was last updated on 3/8/2024.

Stephen K. Brannan Insider Trading History at Karuna Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/8/2024Sell5,000$318.34$1,591,700.0042,604View SEC Filing Icon  
2/8/2024Sell5,000$316.13$1,580,650.0041,150View SEC Filing Icon  
1/8/2024Sell15,000$316.81$4,752,150.0038,650View SEC Filing Icon  
12/8/2023Sell10,000$202.37$2,023,700.0036,150View SEC Filing Icon  
11/8/2023Sell5,000$177.85$889,250.0033,650View SEC Filing Icon  
10/9/2023Sell5,000$173.24$866,200.0031,150View SEC Filing Icon  
9/8/2023Sell5,000$184.04$920,200.0028,650View SEC Filing Icon  
4/10/2023Sell5,000$176.88$884,400.0023,650View SEC Filing Icon  
3/9/2023Sell5,000$189.51$947,550.0023,650View SEC Filing Icon  
2/9/2023Sell5,000$192.37$961,850.0015,000View SEC Filing Icon  
1/9/2023Sell5,000$197.52$987,600.0015,000View SEC Filing Icon  
12/9/2022Sell5,000$200.76$1,003,800.0015,000View SEC Filing Icon  
11/9/2022Sell5,000$216.00$1,080,000.0015,000View SEC Filing Icon  
10/10/2022Sell5,000$207.51$1,037,550.0015,000View SEC Filing Icon  
9/9/2022Sell5,000$243.46$1,217,300.0015,000View SEC Filing Icon  
8/9/2022Sell25,000$228.08$5,702,000.0015,000View SEC Filing Icon  
7/11/2022Sell15,000$133.29$1,999,350.0015,000View SEC Filing Icon  
6/9/2022Sell5,000$110.90$554,500.0015,000View SEC Filing Icon  
5/9/2022Sell5,000$104.10$520,500.0015,000View SEC Filing Icon  
4/1/2022Sell7,728$128.45$992,661.6015,000View SEC Filing Icon  
3/1/2022Sell7,728$107.38$829,832.64View SEC Filing Icon  
2/1/2022Sell7,728$110.05$850,466.40View SEC Filing Icon  
1/3/2022Sell7,728$130.79$1,010,745.12View SEC Filing Icon  
12/1/2021Sell7,728$127.57$985,860.96View SEC Filing Icon  
7/1/2020Sell7,728$108.53$838,719.8415,000View SEC Filing Icon  
6/1/2020Sell7,728$90.64$700,465.9212,500View SEC Filing Icon  
5/1/2020Sell7,728$79.38$613,448.6410,000View SEC Filing Icon  
4/1/2020Sell7,728$67.36$520,558.087,500View SEC Filing Icon  
See Full Table

Stephen K. Brannan Buying and Selling Activity at Karuna Therapeutics

This chart shows Stephen K Brannan's buying and selling at Karuna Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Karuna Therapeutics Company Overview

Karuna Therapeutics logo
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $329.83
Low: $329.83
High: $329.83

50 Day Range

MA: $327.01
Low: $313.97
High: $329.83

2 Week Range

Now: $329.83
Low: $158.38
High: $329.99

Volume

5 shs

Average Volume

832,048 shs

Market Capitalization

$12.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18